Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (2): 184-188.doi: 10.12092/j.issn.1009-2501.2018.02.013

Previous Articles     Next Articles

Protective effects of liraglutide on myocardium of AMI patients with the treatment of PCI

WEI Yuqiang   

  1. The Affiliated Hospital of Hangzhou Normal University, Emergency Department, Hangzhou 310011, Zhejiang, China
  • Received:2017-08-14 Revised:2017-10-18 Online:2018-02-26 Published:2018-03-02

Abstract:

AIM: To investigate the protective effects of liraglutide on myocardium in acute myocardial infarction (AMI) patients treated with percutaneous coronary intervention (PCI).  METHODS: One hundred and ten cases of patients diagnosed as AMI, complicated with stress hyperglycemia and treated with PCI were divided into two groups, 55 cases each. Besides standard treatments, observation group was treated with liraglutide while control group was treated with insulin. Factors including creatine phosphokinase (CK), creatine kinase isoenzymes (CKMB), serum cardiac troponin T (cTnT), high-sensitivity C-reactive protein (hs-CRP), nitrogen terminal pro-brain natriuretic peptide (NT-pro-BNP), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and myocardium perfusion defect score were tested before and after treatment between the two groups to compare the efficacy of the two therapeutics. RESULTS:After the surgery, CK, CKMB, cTnT and hs-CRP significantly increased (P<0.05) while NT-pro-BNP decreased significantly (P<0.05) in both groups, and the 48 h peak values of these factors in observation group were significantly lower than those in the control group (t=5.188, 7.081, 2.180, 5.091, 4.748, P<0.05). Compared within groups, the myocardial perfusion defect score at day 30 decreased as compared with day 7 both in the control group (significantly, t=7.963, P<0.05) and in the observation group (not obviously, P>0.05). Compared between the groups, the index in the observation group were lower than that in the control group both at day 7 (significantly, t=6.235, P<0.05) and day 30 (not obviously, P>0.05). LVEF, LVEDD at day 30 increased compared with the indexes at day 7 in both groups, and the differences in the control group were significant (t=6.235, P<0.05). Comparison within the groups showed significant difference between the 30 d LVEF (t=2.032, P<0.05), while other differences were not significant (P>0.05). CONCLUSION: Liraglutide exhibits protective effects on myocardium of AMI patients treated with PCI.

Key words: AMI, liraglutide, PCI, myocardial perfusion defect

CLC Number: